Patricia Galván
Publicacions destacades
-
A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Autors:Referència: Annals Of Oncology 2018. -
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Autors:Referència: Cancer Research 2017. -
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
Autors:Referència: Stem Cell Reports 2017. -
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer.
Autors:Referència: Cancer Research 2017. -
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial
Autors:Referència: Lancet Oncology 2017. -
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer
Autors:Referència: Oncotarget 2017. -
Identification of ALK, ROS1 and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Autors:Referència: Clinical Chemistry 2017. -
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Autors:Referència: Jama Oncology 2016. -
Intrinsic subtype and gene expression changes between primary and metastatic breast cancer
Autors:Referència: Cancer Research 2016. -
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
Autors:Referència: Cancer Research 2016.
Projectes destacats
-
Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS
Finançador: Fundación Mutua Madrileña (Sede o evento)Durada: 01/01/2018 - 01/01/2021 -
Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS
Finançador: Fundación Quirón Salud (Sede o evento)Durada: 01/01/2018 - 01/01/2021 -
Doble bloque Her2 sin quimioterapia en cáncer de mama precoz Her2+
Finançador: Instituto de Salud Juan Carlos III. Ministerio de Economia y Competitividad. (Sede o evento)Durada: 01/01/2017 - 01/01/2019 -
FERP - Construcción y evaluación de linfocitos T con un receptor quimérico antigénico (CART) anti-HER2 para el tratamiento de tumores sólidos HER2-positivos
Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); FERPDurada: 01/01/2016 - 01/01/2017 -
BCRF - Financial Support for the Breast Cancer Intergroup Correlative Science Studies
Finançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); BCRF. University of MichiganDurada: 01/10/2014 - 30/09/2016